Search Within

Paul K Paik

Formats
  1. Meeting Abstract (168)
  2. Journal Article (84)
  3. Review (5)
  4. Book Section (1)
Groups
  1. Department of Medicine (258)
  2. Solid Tumor Oncology Division (258)
  3. Thoracic Oncology (258)
  4. GSK Faculty (77)
  5. Department of Pathology and Laboratory Medicine (73)
  6. Human Oncology and Pathogenesis Program (55)

More Groups

People
  1. Mark Kris (55)
  2. Marc Ladanyi (47)
  3. Gregory Riely (42)
  4. Natasha Rekhtman (41)
  5. Charles Rudin (40)
  6. Jamie Chaft (33)

More People

Years
  1. 2025 (8)
  2. 2024 (15)
  3. 2023 (32)
  4. 2022 (39)
  5. 2021 (34)
  6. 2020 (18)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (49)
  3. Annals of Oncology (34)
  4. Clinical Cancer Research (12)
  5. International Journal of Radiation Oncology, Biology, Physics (11)
  6. Clinical Lung Cancer (6)

More Publications

Publishers
  1. Elsevier Inc. (82)
  2. American Society of Clinical Oncology (56)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (22)
  5. Wiley Blackwell (12)
  6. Nature Publishing Group (11)

More Publishers

Results (258)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib
    Journal Article

    Paik, P. K.; Goyal, R. K.; Cai, B.; Price, M. A.; Davis, K. L.; Ansquer, V. D.; Caro, N.; Saliba, T. R.
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Clinical response to tepotinib according to circulating tumor (ct)DNA biomarkers in patients with advanced/metastatic NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx)
    Meeting Abstract

    Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Cabrera-Galvez, C.; Baz, D. V.; Kim, Y. C.; Kang, J. H.; Stroh, C.; Juraeva, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, open-label phase 2 study of the TORC 1/2 inhibitor sapanisertib in relapsed/refractory (R/R) NFE2l2 (NRF2)-mutated and wild-type (WT) squamous non-small cell lung cancer (sqNSCLC)
    Meeting Abstract

    Riess, J. W.; Johnson, M. L.; Gadgeel, S.; Skoulidis, F.; Sumrow, B.; Kuriakose, E.; Albert, K.; Kittrell, N.; Akella, L.; Fiji, G.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: Clinicopathological and genomic features of 14 rare biphenotypic tumours
    Journal Article

    Savari, O.; Febres-Aldana, C.; Chang, J. C.; Fanaroff, R. E.; Ventura, K.; Bodd, F.; Paik, P.; Vundavalli, M.; Saqi, A.; Askin, F. B.; more...
    Histopathology (2023)

    Fulltext@MSK | Save
  • SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors
    Journal Article

    Sato, H.; Kubota, D.; Qiao, H.; Jungbluth, A.; Rekhtman, N.; Schoenfeld, A. J.; Yu, H. A.; Riely, G. J.; Toyooka, S.; Lovly, C. M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Garassino, M. C.; Le, X.; Iam, W. T.; Felip, E.; Sakai, H.; Veillon, R.; Smit, E. F.; Mazieres, J.; Raskin, J.; Cortot, A. B.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of tepotinib with capmatinib in previously treated advanced non-small cell lung cancer (aNSCLC) with met exon 14 (METex14) skipping
    Meeting Abstract

    Paik, P.; Pfeiffer, B.; Vioix, H.; Postma, M. J.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
    Meeting Abstract

    Yang, J. C. H.; Kato, T.; Ahn, M. J.; Sakai, H.; Morise, M.; Chen, Y. M.; Han, J. Y.; Yang, J.; Zhao, J.; Huang, J. L. C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Interim analysis of VISION cohorts A and C
    Meeting Abstract

    Griesinger, F.; Thomas, M.; Reinmuth, N.; Wermke, M.; Overbeck, T.; Alt, J.; Henschke, S.; Wehler, T.; Ochsenreither, S.; Garassino, M. C.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save